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There is no consensus and a limited evidence base for choice of contrast agents (CA) in
angiography. This study evaluated the impact of iohexol and iodixanol CA on fibrinolytic fac-
tors (tissue plasminogen activator [t-PA] and plasminogen activator inhibitor-1 [PAI-1]), as
well as platelet-monocyte conjugates in cardiac patients undergoing elective angiography
in a double-blind, randomised parallel group study.
Methods
Patients (men, 50–70 years old; n = 12) were randomised to receive either iohexol (Omnipa-
que; n = 6) or iodixanol (Visipaque; n = 6) during elective angiography at Raigmore Hospital,
Inverness, UK. Arterial and venous blood samples were drawn prior to CA delivery and fol-
lowing angiography. Assessment of platelet-monocyte conjugation, t-PA and PAI-1 antigen
and activity was conducted in samples pre- and post-angiography.
Outcome
Plasma t-PA antigen was depressed equally in the study groups after angiography, but
there was a greater reduction in PAI-1 antigen in the group receiving iodixanol. These find-
ings corresponded to a substantial reduction in t-PA activity in patients receiving iohexol,
with no change in those receiving iodixanol (P = 0.023 between the CA groups). Both CAs
caused a reduction in platelet-monocyte conjugation, with no difference between the
groups. No adverse events were reported during the trial.
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Conclusion
Avoiding reduced plasma t-PA activity might be an important consideration in choosing
iodixanol over iohexol in patients at risk of thrombosis following angiography. The trial is
registered on the ISRCTN register (ISRCTN51509735) and funded by the Coronary Throm-
bosis Trust and National Health Service (Highland) R&D Endowments. The funders had no




There is considerable debate over the relative merits of the various contrast agents (CAs) used
routinely in cardiology to enhance definition of coronary arteries for diagnostic angiography
and for interventional techniques (angioplasty and stenting). Early research focused on com-
parisons of ionic (e.g. ioxaglate) and non-ionic (e.g. iohexol; Omnipaque™) CAs; iohexol was
found to have a moderately better haemodynamic profile than ioxaglate [1]. Thrombogenicity
is considered to be a risk of CA use, but the data are contradictory: non-ionic iopamidol was
found to generate more thrombus than ionic diatrizoate in patients undergoing intervention
procedures, but use of non-ionic iohexol during high risk percutaneous transluminal coronary
angioplasty was associated with reduced incidence of major adverse cardiac events (MACE;
5.4%), compared to ioxaglate (9.5%) [2]. The notion that modulation of thrombotic potential
is central to differential risk associated with CA [3] gave rise to a number of in vitro studies to
determine the impact of CA on platelet function. However, the direct inhibitory effects of CA
on platelet activation in vitro [4, 5] do not reflect the clinical data. Indeed, ioxaglate has been
shown to have a powerful inhibitory effect on thrombus formation in vitro, while non-ionic
CA actively induce formation of thrombus that is particularly resistant to thrombolysis [6].
Iohexol-induced resistance to thrombolysis might be compounded in vivo because iohexol,
but not ioxaglate, increases plasminogen activator inhibitor 1 (PAI-1) [7], with the potential
to reduce fibrinolysis and increase thrombotic risk—a finding that contradicts clinical out-
comes [2].
More recently, another category of CA has emerged—the non-ionic dimers (e.g. iodixanol;
Visipaque™). Evidence suggests that iodixanol has a favourable outcome profile in coronary
angiography, not only compared to ionic ioxaglate in high-risk patients undergoing coronary
angioplasty [2], but also compared to the non-ionic monomer, iohexol, especially in patients
with unstable angina [8]. In vitro platelet studies do not provide a clear answer as to how the
benefits of iodixanol are realised: thrombus formation has been found to be more substantial
with this CA than with either iohexol or ioxaglate, but iohexol had the additional disadvantage
of enhanced platelet degranulation [6]. However, other studies have shown a reduced impact
of iodixanol on platelet activation than iohexol or diatrizoate [9] and a less detrimental effect
in cultured endothelial cells than either iohexol or ioxaglate [10]. An impact of CA on the
endothelium provides a particularly interesting route to thrombosis because endothelial cells
can influence platelet function both through release of pro- and anti-platelet mediators (e.g.
nitric oxide, prostacyclin, thromboxane A2) [11], and through generation of pro- and anti-
fibrinolytic factors—tissue plasminogen activator (t-PA) [12] and plasminogen activator
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inhibitor 1 (PAI-1) [13], respectively. Endothelial function is also highly responsive to oxygen-
centred free radicals (oxidative stress) and inflammation [11], both of which have been impli-
cated in the aetiology of CA-induced nephrotoxicity.
Here, we tested the hypothesis that iodixanol, but not iohexol, influences the release of t-PA
and PAI-1 to favour increased fibrinolysis in patients undergoing elective coronary angiogra-
phy. In addition, we measured platelet-monocyte conjugates as a recognised surrogate for car-
diovascular risk [14–19]. Given the well-recognised sensitivity of both the endothelium and
platelets to oxidative stress, oxygen-centred free radical generation from iodixanol and iohexol




Ethical approval from the North of Scotland Research Ethics Committee (REC: 11/S0802/14,
IRAS ID: 70700) was obtained in advance of the study (approval date 24/3/2011), which com-
plied with the Declaration of Helsinki and its amendments. All patients gave written, informed
consent. The formal study completion date was 1st May 2013. The trial is registered on the
ISRCTN register (ISRCTN51509735). Trial registration was retrospective because planning for
the study began in 2010, before trial registration for small investigator led single site studies
was the norm. The authors confirm that all ongoing and related trials for this intervention are
registered. The ethics protocol is included in (S1 File).
Patients
Informed consent was obtained from patients with coronary artery disease attending Raigmore
Hospital, Inverness, UK between June and July 2011. Inclusion criteria for the study were:
men, 50–70 years old, prescribed aspirin and scheduled for coronary angiography. Patients
prescribed clopidogrel and those who had taken part in any study in the previous 3 months
were excluded. Patients were requested to abstain from alcohol and caffeine 12 h prior to angi-
ography and were randomised to receive either iohexol (Omnipaque™ 300 mg I/ml) or iodixa-
nol (Visipaque™ 320 mg I/ml). The volume of CA received varied according to need during the
procedure (minimum 40 mL, maximum 185 mL; see Table 1 for mean data). On each study
day, notes from up to 4 patients on the clinical angiogram list for that morning were consulted
to assess eligibility against the inclusion and exclusion criteria (Fig 1). The first patient on each
day that was eligible for the study was invited to participate. All patients who were approached
to participate in the study consented. Only one patient was recruited on each study day; only
patients scheduled for morning angiograms were recruited to the study to minimise the impact
of circadian variation on fibrinolytic [20, 21], platelet [22] and endothelial [23, 24] function.
The Consort checklist is included in (S2 File).
Power calculation, randomization, blinding
A power calculation was performed using the SD from published data from a related study
with PAI-1 as an outcome measure [7], using Lehr’s formula. On the basis of the calculation, it
was determined that 6 patients would be required in each group to give 80% power of detecting
a 50% change in PAI-1 at the P<0.05 confidence level. Patients were randomized to receive
either iohexol or iodixanol by a researcher independent to the study using a random number
generator. Researchers and patients were blinded as to which CA was used–each patient was
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assigned a code number and none of the researchers had access to the key; unblinding took
place after analysis of the data was complete for the whole study.
Blood sampling and laboratory analyses
Blood (25 ml) was sampled from both 5F arterial sheath and 21G venous peripheral venous
cannula (in the antecubital fossa) at baseline (immediately prior to CA injection) and immedi-
ately following angiography (the time between samples was typically ~20–30 min). At each
draw, the first 10 ml of blood was discarded. An aliquot of samples was taken into lithium-hep-
arin tubes (Monovette1) for flow cytometry assessment of platelet-monocyte conjugation,
whilst a second aliquot was taken into citrate tubes (pH 4.3) prior to centrifugation (5000 g, 10
min) and isolation of plasma that was immediately frozen and stored in advance of batch-test-
ing for t-PA and PAI-1 antigen and activity (Zymutest, Quadratech Diagnostics). Flow cytome-
try was carried out within 1 h of sampling: whole blood samples (50 μl) were dual-stained by
incubating with CD14-FITC (BD 555397) and CD41a-PE-Cy5 (BD 559768) antibodies, or the
appropriate isotype controls for 15 min. Samples were incubated for a further 15 min with
FACS lysing solution (0.5 ml; BD) and then immediately analysed for conjugates using a
FACSCalibur flow cytometer (Becton Dickinson). Platelet-monocyte conjugates were identi-
fied as CD14/CD41a–positive events [14].
Protein Estimation
Plasma protein was estimated using Coomassie Plus protein assay reagent (Thermo Scientific).
Briefly, citrated plasma samples were diluted 1:50 in PBS and 2 μl transferred to duplicate wells
of a 96-well plate. To each well, 100 μl of Coomassie reagent was added, mixed and incubated
for 10 min at room temperature before reading at λ = 595 nm using a Varioskan plate reader
(Thermo). Sample protein values were estimated from the standard curve using the plate
reader software.
Table 1. Patient characteristics.
Iohexol (Omnipaque) Iodixanol(Visipaque)
Patients recruited (n) 6 6
Evaluable patient number (n) 6 6
Age (yrs±SD) 65.5±6.5 67.5±7.4NS
BMI (±SD) 26.9±6.2 33.8±7.2NS
SBP (mmHg; ±SD) 154±24 146±11NS
DBP (mmHg; ±SD) 77±12 80±10NS
Hypertension (n) 2 2NS
Aspirin (n) 6 6NS
ACE inhibitors (n) 1 2NS
Ang II receptor antagonists (n) 1 1NS
β-blockers (n) 2 3NS
Calcium antagonists (n) 1 2NS
Statins (n) 5 6NS
Nitrates (n) 0 1NS
Contrast volume received (ml) 73±9 99±19NS
NS Not statistically different from iohexol group (Student’s t-test for continuous data, χ2 test for categorical
data).
doi:10.1371/journal.pone.0147196.t001
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Oxygen-centred radical generation from iohexol and iodixanol (EPR
spectrometry)
Electron paramagnetic resonance (EPR) spectrometry was used to establish the rate of genera-
tion of oxygen-centred radicals from iohexol and iodixanol. This in vitro assay involved dilu-
tion of CA to 80% v/v using phosphate-buffered saline (PBS) to facilitate uptake into capillary
tubes (50 μl) prior to incubation with an oxygen-centred radical-specific spin trap (Tempone-
H; 1 mM) at 37°C. Parallel experiments with and without vitamin C (200 μM) were conducted
Fig 1. Flow diagram for patient recruitment, enrolment and participation in the study.
doi:10.1371/journal.pone.0147196.g001
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to examine the impact of an antioxidant on the signals generated. Samples were measured at 15
min intervals for 1 h in an EPR spectrometer (MS200 miniscope spectrometer; Magnettech,
Germany; parameter settings: B0-field, 335.6mT; sweep width, 5 mT; sweep time, 30 sec; mod-
ulation amplitude, 0.15 mT; microwave power, 20 mW; microwave frequency, 9.3 GHz). The
principle of the assay is that oxygen-centred radicals react with the spin trap to generate a spin-
adduct (4-oxo-tempo), which is a stable free radical that generates a characteristic EPR spec-
trum [25] when excited with microwaves. The amplitude of the signal is directly proportional
to the concentration of the spin adduct, allowing accurate comparisons of the rate of radical
generation in the samples.
Data and Statistics
Data are presented as mean±SD (Table 1) and mean±SE (Figs 2–4). Patient characteristics
(Table 1) and data in Fig 4 are compared with two-tailed, unpaired Student’s t-test (continuous
data sets) and χ2 for categorical data sets. Data in Figs 2 and 3 are compared using 2-factor
ANOVA (repeated measures) and those in Fig 5 using one-factor ANOVA. P<0.05 was
accepted as significant in all cases.
Results
Patient characteristics, pre-existing drug regimens and CA volume used are described in
Table 1. No adverse events were reported in the trial. There was no significant dilution of
plasma proteins in patients receiving either iohexol or iodixanol (S1 Table).
t-PA and PAI-1 antigen and activity
Plasma t-PA antigen was reduced in both arterial and venous samples, but the extent of the
reduction was smaller in arterial compared to venous samples, both in absolute and % baseline
(~8% arterial, ~17% venous; S1 Table) terms. There was no statistical difference between the
changes in plasma t-PA antigen following iohexol compared to iodixanol (Fig 2A).
Plasma PAI-1 antigen was also reduced in both arterial and venous samples in patients
receiving iohexol or iodixanol. Although there was an apparent difference between the treat-
ment groups with respect to PAI-1 antigen in the venous samples, this did not reach statistical
significance (Fig 2B). The mean % reduction in PAI-1 antigen ranged from ~4–19% across the
groups (S2 Table).
t-PA activity in the iodixanol group was relatively unaffected in arterial or venous samples
post-angiogram, in keeping with equivalent reductions in both t-PA and PAI-1 antigen in this
group. However, t-PA activity was significantly supressed in the group that received iohexol
(Fig 3A), reflecting the imbalance between the reduction in t-PA antigen and that of PAI-1.
The reverse was found for PAI-1 activity, where there was a significantly greater reduction in
PAI-1 activity associated with the group that received iodixanol (Fig 3B). Raw data are available
in (S3 Table).
Platelet-monocyte conjugates
Platelet-monocyte conjugates were not significantly reduced in post-angiogram venous sam-
ples from patients receiving iohexol (Fig 4A), but this measure was significantly reduced in
those receiving iodixanol (Fig 4B). There was no significant difference between the extents of
reduction in platelet-monocyte conjugate counts in the two groups (Fig 4C). Raw data are
available in (S4 Table).
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Oxygen-centred radical generation from iohexol and iodixanol
In vitro generation of oxygen-centred free radicals was measured in samples of iohexol and
iodixanol incubated in the dark at 37°C. Iohexol was found to generate free radicals at a consid-
erably faster (~x4) rate than iodixanol (Fig 5A). Fig 5B shows the reduction in EPR signal
intensity generated by iohexol in the presence of the antioxidant, vitamin C (200 μM), and the
very low signal intensity generated by iodixanol after 60 min incubation. Raw data are available
in (S5 Table).
Fig 2. Change in (A) t-PA and (B) PAI-1 antigen in arterial and venous blood samples post-
angiography compared to baseline in patients receiving iohexol and iodixanol. There was no significant
difference between the groups (2-way repeated measures ANOVA, P value shown is between treatment
groups; n = 6 in each group). There was no interaction between treatment groups and arterial/venous
plasma.
doi:10.1371/journal.pone.0147196.g002
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Discussion
The choice of CA in the cardiology setting is founded on a limited evidence base and the merits
of each are debated. This study examined the differences between two of the most commonly
used CA, iohexol and iodixanol, on factors central to the fibrinolytic process and on platelet-
monocyte conjugation as a marker of thrombotic risk, with a view to informing the debate over
CA choice.
Fig 3. Change in (A) t-PA and (B) PAI-1 activity in arterial and venous blood samples post
angiography compared to baseline in patients receiving iohexol and iodixanol. t-PA activity was
significantly reduced in the iohexol group; PAI-1 activity was significantly reduced in the iodixanol group
(2-way repeated measures ANOVA, P value shown is between treatment groups; n = 6 in each group). There
was no interaction between treatment groups and arterial/venous plasma.
doi:10.1371/journal.pone.0147196.g003
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Fig 4. Effect of angiography (post-angio) on platelet-monocyte conjugation in patients exposed to (A) iohexol
and (B) iodixanol compared to baseline (pre-CA); *P<0.05. The% reduction in platelet-monocyte conjugation
is shown in (C). n = 6 in each group; NS—P>0.05.
doi:10.1371/journal.pone.0147196.g004
Contrast Media and Fibrinolytic Factors
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The key findings were that t-PA activity was reduced in patients receiving iohexol, but
remained unchanged in those receiving iodixanol. Platelet-monocyte conjugation was substan-
tially reduced following angiography, but there was no difference between the extent of conju-
gate reduction in the groups receiving different CAs. Iohexol also generated oxygen-centred
free radicals at a substantially faster rate than iodixanol in vitro.
t-PA is a crucial endothelium-derived fibrinolytic factor that activates the conversion of
plasminogen to plasmin. Activity of t-PA is modulated by PAI-1, a factor that is also generated
by the endothelium as well as by activated platelets. PAI-1 conjugates with t-PA to inactivate it;
the balance of these two factors is central to determining the extent of fibrinolysis. Ionic and
non-ionic CAs differentially affect PAI-1; iohexol has been found to have a detrimental effect
with respect to PAI-1 release compared to ioxaglate [7]. The current study investigated the
newer non-ionic dimeric CA, iodixanol, to establish if it behaved in the same way as iohexol
with respect to PAI-1 generation. Our findings indicate that iodixanol has little impact on the
balance of t-PA to PAI-1, whereas iohexol causes a net reduction in t-PA activity. Although
both iohexol and iodixanol reduce t-PA antigen, t-PA activity remains unchanged in the iodix-
anol group on account of equivalent modulation of PAI-1 release. Iohexol, on the other hand,
induces a larger reduction in t-PA antigen than PAI-1 antigen, resulting in the measurable loss
in t-PA activity. The effects seen were not confounded by circadian fluctuations [20, 21]
Fig 5. (A) In vitro oxygen-centred free radical generation in samples of CA at 37°C. Iohexol generates free
radicals at a significantly higher rate than iodixanol (n = 4; P<0.001). (B) Representative EPR spectra
obtained for iodixanol alone, iodixanol + vitamin C (200 μM) and iohexol after 60 min incubation (37°C) with
the oxygen-centred radical spin trap, tempone-H (1 mM). The characteristic 3-line spectrum is representative
of formation of the stable radical adduct, 4-oxo-tempone, via reaction with oxygen-centred radicals; the
amplitude of the signal is proportional to the amount of 4-oxo-tempone present.
doi:10.1371/journal.pone.0147196.g005
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because all angiograms were conducted in the morning and the pre- and post-angiogram sam-
ples were drawn only 20–30 min apart. That non-ionic iodixanol more closely aligns with ionic
ioxaglate [7] than with non-ionic iohexolin in this regard suggests that the effects of CAs on
fibrinolytic factors are not related to their ionic characteristics. Nor does it appear that the
effects are mediated by a dilution effect of CA administration, given that plasma protein was
not significantly affected by either CA. Instead, it seems that chemical characteristics specific to
iohexol drive a net loss in t-PA activity on account of a mis-match between loss of t-PA antigen
and PAI-1 antigen. The reduced PAI-1 activity in our study was at odds with the findings of a
previous study [7], in which PAI-1 activity was found to increase with iohexol; the major differ-
ence between the two studies was the patient group (suspected pulmonary embolism as
opposed to coronary artery disease) and it is plausible that fibrinoloyic factors could be differ-
entially affected in these quite diverse patient groups. The impact of reduced t-PA activity with
iodixanol in vivo would compound the recognised resistance of thrombi formed with non-
ionic CA to thrombolysis in vitro [6]. These characteristics, coupled with a reduced propensity
to platelet degranulation [6], might help to explain the improved outcome in patients receiving
iodixanol compared to those receiving iohexol.
Platelet function has long been known to be affected by CAs, but this is the first study to
measure platelet-monocyte conjugation as a marker of thrombotic potential. Exposure to both
CAs reduced platelet-monocyte conjugates, suggesting an antithrombotic effect, although sta-
tistical significance was only reached for iodixanol in this small study. There was no significant
difference between the extents of reduced platelet-monocyte conjugation between the two CAs
tested. These findings are in agreement with previous data suggesting that CAs have antiplate-
let effects in vitro [4, 5].
Taking into account both the platelet-monocyte conjugation and the fibrinolytic factor data,
it can be surmised that CAs might reduce risk of thrombosis in the short term but that, should
a thrombotic event occur, patients receiving iohexol might suffer more severe effects on
account of depressed fibrinolytic defence. The findings shift the emphasis of CA-induced dys-
function away from platelets and towards the endothelium, as the principal source of t-PA and
PAI-1, and the vasoactive factors that it generates.
Endothelial activity is highly sensitive to oxidative stress, so we explored whether there were
differences in oxygen-centred free radicals generation from iohexol and iodixanol that might
contribute to the effects seen. Previous findings suggest that CAs have an antioxidant effect
overall and that iodixanol is more potent in this regard than iohexol [26], but the current study
indicates that iohexol induces substantial spontaneous oxygen-centred free radical formation
compared to iodixanol; the radical production is partially quenched by a moderate concentra-
tion of the antioxidant, vitamin C, confirming that the signal is mediated by oxygen-centred
radical generation.
At present, we have no evidence to link the free radical generation seen with iohexol to
endothelial dysfunction or to the impact on PAI-1 and t-PA. However, the current data could
provide an explanation as to why there are differential effects of these CAs on release of fibrino-
lytic factors. The hypothesis that oxygen-centred radical generation from iohexol drives endo-
thelial dysfunction with respect to release of fibrinolytic factors is worthy of further
investigation.
Study limitations
This was a small, but adequately powered study for the primary outcomes. In addition, the
study was only conducted in men undergoing elective angiography. A large, multi-centre trial
is justified to determine whether the results are reproduced at scale.
Contrast Media and Fibrinolytic Factors
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Conclusions
Iohexol and iodixanol both induced an inhibitory effect on platelet-monocyte conjugation, sug-
gestive of an anti-thrombotic effect of both CAs. However, iohexol also induced a significant
reduction in t-PA activity compared to iodixanol, implying that fibrinolytic capability is
impaired after use of this agent. These findings contribute to the debate over which CA to use
and justify a larger outcome study to establish whether the physiological changes reflect in
major adverse coronary events, which could help cardiologists to make fully informed deci-
sions regarding which CA to use in clinical practice.
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